SAB BIO

We're having an incredible time at #EASD2024. Thank you to the European Association for the Study of Diabetes e.V. (EASD)for putting this event together. It is fantastic to learn from, connect with, and build relationships with other #type1diabetes stakeholders—see the pics of our own Christoph Bausch, PhD, MBA and Alexandra Kropotova, MD, MBA below on-site!

Today, we announced an important #clinicaltrial progress update at European Association for the Study of Diabetes e.V. (EASD) annual meeting. Our SAB-142 program has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is progressing to enroll patients with #type1diabetes in the last cohort of the study, with no observation of serum sickness at the targeted dose. It's an exciting year for SAB! We remain on track for a topline Phase 1 data readout by the end of the year. See link for more details in release! https://lnkd.in/eF4hT6fw

We look forward to connecting with other #diabetes leaders at the #easd2024 symposium next week in Madrid for the European Association for the Study of Diabetes e.V. (EASD). Our Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA, will present on September 9 at 8:45 a.m. Please stop by to hear more about our exciting work with SAB-142, our #t1d therapy!

This morning, we announced a new clinical advisory board, created to provide expert insight and guidance to the Company in the clinical development of SAB-142, our leading therapeutic candidate. Read more about the release and founding members of the Board here: https://lnkd.in/eBczZSXA

We are pleased to welcome @Lucy To as our newly appointed CFO, effective August 12. Lucy joins SAB with more than 18 years of investment banking and strategic operational expertise to SAB and will lead corporate finance, corporate strategy and approach to broader strategic business relationships at the company. Read more about her joining SAB in the release found here: https://lnkd.in/dkHPUyH2

SAB was featured in the latest publication of Refresh Miami - link below!

What an incredible week we've had attending American Diabetes Association #adascisessions and meeting reknowned #type1diabetes advocates, researchers and thought leaders. Attending SAB BIO representatives included our Chairman and CEO Samuel Reich, our Co-Founder and President Eddie J Sullivan, EVP and COO Christoph Bausch, VP of Clinical Operations Angela Parizek, VP of Clinical Development Stan Stoyanov MD, MBA, and Senior Program Manager Eric Sandhurst, PhD. We look forward to continuing to build relationships with the other attendees we met. See you next year!

We've met so many incredible #type1diabetes advocates during the American Diabetes Association #ADAscisessions, and today SAB Senior Program Manager Eric Sandhurst, PhD presented in the Poster Hall and took questions. Also pictured below is our COO & EVP, Christoph Bausch. We'll be here one more day in the Poster Hall at 885-P if you'd like to check out our presentation. Come say hello!

We are excited to announce we have evolved our name and visual identity! This is an important milestone, reflecting our strategic evolution and focus on addressing serious unmet needs in #type1diabetes. We look forward to showcasing our new branding during our poster presentation at the American Diabetes Association  84th Scientific Sessions on June 21-24, 2024 in Orlando, Florida and hope to see you there! Read more about this announcement and check out our website at sab.bio. #t1d #type1diabetes #diabetes #ADASciSessions

We are pleased to note our upcoming poster presentation at this week's American Diabetes Association #scientificsessions in Orlando on Sunday, June 23 for #ADA2024. Details about where to find our poster and connect with the presenter can be found below. https://lnkd.in/eX58xMxh